相关实验视频
Updated: Jul 1, 2025
03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
411
罗米德素通过DDIT4-mTORC1通路表现出抗食道状细胞癌的活性
Wei-Feng Xia1, Xiao-Li Zheng2, Wen-Yi Liu2
1Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Cancer gene therapy
|March 14, 2024
概括
罗米德素是一种基因素脱乙酶抑制剂,显示出治疗食道状细胞癌 (ESCC) 的前景. 这种药物在临床前模型中降低了癌细胞活力和瘤生长,为ESCC提供了潜在的新疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 食道状细胞癌 (ESCC) 是一种流行且致命的癌症,治疗选择有限.
- 对于对抗ESCC的新型治疗药物有着至关重要的需求.
- 准细胞通路为开发新的抗癌药物提供了一个有希望的途径.
研究的目的:
- 通过高通量药物查,识别具有抗ESCC活性的新型化合物.
- 在ESCC的临床前模型中研究罗米德素的治疗潜力.
- 阐明罗米德素抗ESCC作用背后的分子机制.
主要方法:
- 在2D和3D培养中对ESCC细胞系进行化合物的高通量药物查 (HTS).
- 在体外测试评估细胞活力,细胞亡和细胞循环进展.
- 在体内研究使用ESCC细胞系衍生异种移植 (CDX) 和患者衍生异种移植 (PDX) 的小鼠模型.
- 分子分析包括基因表达和通路分析 (mTORC1).
主要成果:
- 罗米德素通过HTS被确定为一种强大的抗ESCC剂.
- 罗米德素降低了ESCC细胞活力,诱导了细胞亡,并导致细胞循环停止.
- 罗米德素通过激素过乙化上调调节DDIT4基因表达,抑制mTORC1通路.
- 在PDX模型中,罗米德素与传统药物相比,表现出更高的疗效和安全性.
结论:
- 罗米德素是食道状细胞癌治疗的有希望的候选药物.
- 该药物的机制涉及DDIT4诱导和mTORC1抑制.
- 罗米德素显示出作为ESCC患者的新疗法选择的潜力.
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:31Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K